U.S. markets closed
  • S&P 500

    4,173.85
    +61.35 (+1.49%)
     
  • Dow 30

    34,382.13
    +360.68 (+1.06%)
     
  • Nasdaq

    13,429.98
    +304.99 (+2.32%)
     
  • Russell 2000

    2,224.63
    +53.68 (+2.47%)
     
  • Crude Oil

    65.51
    +1.69 (+2.65%)
     
  • Gold

    1,844.00
    +20.00 (+1.10%)
     
  • Silver

    27.50
    +0.46 (+1.69%)
     
  • EUR/USD

    1.2146
    +0.0062 (+0.51%)
     
  • 10-Yr Bond

    1.6350
    -0.0330 (-1.98%)
     
  • GBP/USD

    1.4102
    +0.0050 (+0.36%)
     
  • USD/JPY

    109.3470
    -0.0870 (-0.08%)
     
  • BTC-USD

    49,049.46
    -2,186.97 (-4.27%)
     
  • CMC Crypto 200

    1,398.33
    +39.77 (+2.93%)
     
  • FTSE 100

    7,043.61
    +80.28 (+1.15%)
     
  • Nikkei 225

    28,084.47
    +636.46 (+2.32%)
     

NIH Starts Study On Allergic Reactions Risk To Pfizer/BioNTech, Moderna COVID-19 Vaccines

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Vandana Singh
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • The National Institutes of Health (NIH) has begun a mid-stage study to determine the risk of allergic reactions shortly after receiving COVID-19 vaccines made by Moderna Inc (NASDAQ: MRNA) and Pfizer Inc (NYSE: PFE)/BioNTech SE (NASDAQ: BNTX).

  • Several allergic reaction incidents, including serious episodes known as anaphylaxis, have been reported in the U.S. after vaccinations of Pfizer/BioNTech and Moderna shots.

  • “The information gathered during this trial will help doctors advise people who are highly allergic or have a mast cell disorder about the risks and benefits of receiving these two vaccines. However, for most people, the benefits of COVID-19 vaccination far outweigh the risks,” said Anthony S. Fauci, M.D., director of the National Institute of Allergy and Infectious Diseases (NIAID).

  • The NIH Phase 2 study will enroll 3,400 adults ages 18 to 69. Participants will be randomly assigned to receive either a Pfizer-BioNTech vaccine, a Moderna vaccine, a placebo followed by a Pfizer-BioNTech vaccine, or a placebo followed by the Moderna vaccine.

  • The trial’s goal is to assess the proportion of participants with a systemic allergic reaction within 90 minutes after injection. Data is expected to be reported later this summer.

  • An independent data and safety monitoring board (DSMB) will review blinded and unblinded study data at scheduled review meetings to ensure study participants’ safety.

  • Price Action: PFE, BNTX, and MRNA shares are down 0.36% at $35.92, 3.82% at $112.68, and 1.21% at $131.92, respectively, during market trading hours on the last check Wednesday.

See more from Benzinga

© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.